According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

Investing.com -- Valneva SE ADR (NASDAQ:VALN) stock tumbled 20.4% premarket Monday after the U.S. Food and Drug ...

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ ®, citing ...